Abstract
This paper summarizes the published Cochrane Review, “Non-pharmacological Care for Opioid Withdrawal in Newborns,” by A. Pahl, L. Young, M. E. Buus-Frank, L. Marcellus, and R. Soll (https://doi.org/10.1002/14651858.CD013217.pub2), and discusses it through a treatment policy and practice lens. The study population in the review included infants born at term (37 weeks’ gestation or greater) and late preterm (34 weeks’ gestation to 37 weeks’ gestation) who had a known or suspected prenatal exposure to opioids or who were exhibiting symptoms consistent with opioid withdrawal in the first 7 days of life. Nonpharmacological interventions included a wide range of care and were broadly categorized as: modification of environmental stimulation, feeding practices, and support of the mother-infant dyad. The review found that randomized controlled trials, identified in searches conducted in October 2019, did not provide enough evidence regarding clinically meaningful outcomes. However, recently published trial data suggest that “Eat, Sleep, Console,” an individualized, trauma-informed, family-centered nonpharmacological approach to care, can reduce the number of days an infant experiencing symptoms consistent with opioid withdrawal requires in-hospital care.
Funder
Research Triangle International
Reference19 articles.
1. 1 Pahl A, Young L, Buus-Frank ME, Marcellus L, Soll R. Non-pharmacological care for opioid withdrawal in newborns. Cochrane Database Syst Rev 2020;12(12):CD013217. 10.1002/14651858.CD013217.pub233348423
2. 2 Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health. HHS Publication No. PEP20-07-01-001, NSDUH Series H-55. Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. 2020. Available from: https://www.samhsa.gov/data/
3. 3 Ko JY, D'Angelo DV, Haight SC, Morrow B, Cox S, Salvesen von Essen B, et al. Vital signs: prescription opioid pain reliever use during pregnancy - 34 U.S. jurisdictions, 2019. MMWR Morb Mortal Wkly Rep 2020;69(28):897-903. 10.15585/mmwr.mm6928a132673301
4. 4 Hirai AH, Ko JY, Owens PL, Stocks C, Patrick SW. Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010-2017. JAMA 2021;325(2):146-55. 10.1001/jama.2020.2499133433576
5. 5 Patrick SW, Barfield WD, Poindexter BB, Committee on Fetus and Newborn, Committee on Substance Use and Prevention, Cummings J, Hand I, et al. Neonatal opioid withdrawal syndrome. Pediatrics 2020;146(5):e2020029074. 10.1542/peds.2020-02907433106341